A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders. AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 61.2B | 61.2B | 56.3B | 54.3B | 58.1B | 56.2B |
| Net Income | 4.2B | 4.2B | 4.3B | 4.9B | 11.8B | 11.5B |
| EPS | $2.36 | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
| Free Cash Flow | 17.8B | 17.8B | 17.8B | 22.1B | 24.2B | 22.0B |
| ROIC | 16.4% | 15.6% | 14.1% | 15.5% | 22.3% | 19.4% |
| Gross Margin | 70.2% | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% |
| Debt/Equity | 0.00 | -20.64 | 20.19 | 6.43 | 3.67 | 4.98 |
| Dividends/Share | $6.51 | $6.65 | $6.29 | $5.99 | $5.71 | $5.31 |
| Operating Income | 15.1B | 15.1B | 9.1B | 12.8B | 18.1B | 17.9B |
| Operating Margin | 24.6% | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| ROE | 0.0% | -129.2% | 128.7% | 46.9% | 68.6% | 74.9% |
| Shares Outstanding | 1,791M | 1,791M | 1,790M | 1,788M | 1,785M | 1,789M |
AbbVie Inc. passes 5 of 9 quality checks, suggesting mixed fundamentals.
AbbVie Inc. trades at 87.5x trailing earnings, compared to its 15-year median P/E of 21.3x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 20.5x vs a median of 10.6x. The company's 5-year average ROIC is 17.4% with a gross margin of 68.3%. Total shareholder yield (dividends + buybacks) is 3.4%. At current prices, the estimated annualized return to fair value is +5.1%.
AbbVie Inc. (ABBV) has a current P/E ratio of 87.5, compared to its historical median P/E of 21.3. The stock is currently considered Expensive based on its historical valuation range.
AbbVie Inc. (ABBV) has a 5-year average return on invested capital (ROIC) of 17.4%. This indicates strong capital allocation and a potential competitive advantage.
AbbVie Inc. (ABBV) has a market capitalization of $369.7B. It is classified as a mega-cap stock.
Yes, AbbVie Inc. (ABBV) pays a dividend with a trailing twelve-month yield of 3.15%. The company also returns capital through share buybacks, with a buyback yield of 0.27%.
Based on historical P/E analysis, AbbVie Inc. (ABBV) appears expensive. The current P/E of 87.5 is 310% above its historical median of 21.3. The estimated fair value CAGR (P/E method) is -7.0%.
AbbVie Inc. (ABBV) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AbbVie Inc. (ABBV) reported annual revenue of $61.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
AbbVie Inc. (ABBV) has a net profit margin of 6.9%. This is a modest margin.
AbbVie Inc. (ABBV) generated $17.8 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
AbbVie Inc. (ABBV) reported earnings per share (EPS) of $2.36 in its most recent fiscal year.
AbbVie Inc. (ABBV) has a return on equity (ROE) of -129.2%. A negative ROE may indicate losses or negative equity.
AbbVie Inc. (ABBV) has a 5-year average gross margin of 68.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for AbbVie Inc. (ABBV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AbbVie Inc. (ABBV) has a book value per share of $-1.83, based on its most recent annual SEC filing.